Using our Arestat™ technology platform, we are developing enhanced medicines for diabetes and other indications through our proprietary pipeline and in partnership with leading pharmaceutical and biotechnology companies

Our Products

Our potential products for diabetes and for specialist hospital use are designed to improve patient outcomes and enable healthier lives

Our Partners

We work with many of the top 20 leading pharmaceutical companies to enhance product formats, find solutions to development challenges and create differentiated products offering the potential for significant improvements in patient safety and convenience

Latest News and Events

  • 22nd October 2021

    Arecor commentary in MedNous on how faster insulin can enable the artificial pancreas

  • 11th October 2021

    ARECOR’S POLYSACCHARIDE VACCINE PATENT UPHELD

  • 20th September 2021

    ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES